TD Cowen analyst Boris Peaker raised the firm’s price target on Ironwood to $10.50 from $9 and keeps a Market Perform rating on the shares. The firm ahead of its Phase 3 apraglutide data from the STARS trial. Cowen anticipates that apraglutide will show efficacy similar to other GLP-2 analogues, which will likely lead to approval and launch in 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IRWD: